New product: Enerzair Breezhaler (indacaterol/ glycopyrronium/ mometasone)

Enerzair Breezhaler is licensed as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long-acting beta2-agonist and a high dose of an inhaled corticosteroid who experienced ≥1 asthma exacerbations in the previous year

Source:

electronic Medicines compendium